FDA approves Empaveli for rare kidney diseases

The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals' Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

AI can help detect kidney cancer faster

Researchers have developed an AI-based tool that accelerates the detection of kidney cancer. Its effectiveness was validated in a study published in Communications Medicine.

High metabolic syndrome severity linked to development of CKD

High metabolic syndrome (MetS) severity, expressed by the continuous metabolic syndrome severity score (cMetS-S), is associated with development of chronic kidney disease (CKD), according to a study recently published in ...

page 8 from 26